Black Diamond Therapeutics (BDTX) Liabilities and Shareholders Equity (2018 - 2026)

Black Diamond Therapeutics (BDTX) has 9 years of Liabilities and Shareholders Equity data on file, last reported at $132.9 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 24.58% year-over-year to $132.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $600.0 million (up 2.26% YoY) and the FY2025 annual result came in at $143.0 million, up 16.61% from the prior year.
• Liabilities and Shareholders Equity eased to $132.9 million in Q1 2026, from $143.0 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $219.5 million in Q1 2022 to a low of $119.9 million in Q2 2023.
• A 5-year average of $157.1 million and a median of $156.3 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity slumped 39.71% — and 2024, when it advanced 25.11%.
• Tracing BDTX's Liabilities and Shareholders Equity over 5 years: stood at $156.3 million in 2022, then grew by 1.48% to $158.6 million in 2023, then dropped by 22.66% to $122.6 million in 2024, then increased by 16.61% to $143.0 million in 2025, then decreased by 7.05% to $132.9 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $132.9 million (Q1 2026), $143.0 million (Q4 2025), and $157.7 million (Q3 2025), per Business Quant data.